SCS
SCS operates in Biotechnology.
SCS - Asset Resilience Ratio
SCS (SCS) has an Asset Resilience Ratio of 0.00% as of June 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2023)
This chart shows how SCS's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down SCS's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 0% |
| Short-term Investments | zł351.36 | 0.0% |
| Total Liquid Assets | zł351.36 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: SCS maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
SCS Industry Peers by Asset Resilience Ratio
Compare SCS's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Macrogen Inc
KQ:038290 |
Biotechnology & Medical Research | 3.56% |
|
Panagene Inc
KQ:046210 |
Biotechnology & Medical Research | 0.14% |
|
Cell Biotech Co. Ltd
KQ:049960 |
Biotechnology & Medical Research | 54.84% |
|
Bioneer Corporation
KQ:064550 |
Biotechnology & Medical Research | 14.92% |
|
MEDIPOST Co. Ltd
KQ:078160 |
Biotechnology & Medical Research | 0.72% |
|
Biotoxtech Co. Ltd
KQ:086040 |
Biotechnology & Medical Research | 7.17% |
|
Peptron Inc
KQ:087010 |
Biotechnology & Medical Research | 57.41% |
|
Hadasit Bio
TA:HDST |
Biotechnology & Medical Research | 57.00% |
Annual Asset Resilience Ratio for SCS (2020–2023)
The table below shows the annual Asset Resilience Ratio data for SCS.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.00% | zł351.36 | zł13.61 Million | +0.00pp |
| 2022-12-31 | 0.00% | zł351.36 | zł14.80 Million | +0.00pp |
| 2021-12-31 | 0.00% | zł351.36 | zł17.08 Million | 0.00pp |
| 2020-12-31 | 0.00% | zł351.36 | zł14.86 Million | -- |